Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enlivex Therapeutics Ltd (NQ: ENLV )

1.350 +0.050 (+3.85%)
Streaming Delayed Price Updated: 1:40 PM EDT, Apr 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 302,770
Open 1.320
Bid (Size) 1.330 (24)
Ask (Size) 1.350 (10)
Prev. Close 1.300
Today's Range 1.320 - 1.418
52wk Range 1.150 - 4.590
Shares Outstanding 18,306,186
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tesla To $180? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga

Performance

YTD
-59.09%
-59.09%
1 Month
-67.70%
-67.70%
3 Month
-52.80%
-52.80%
6 Month
-3.57%
-3.57%
1 Year
-53.21%
-53.21%

More News

Read More
Nasdaq Jumps 250 Points; Crude Oil Down 1%
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Dow Dips 100 Points; CarMax Earnings Miss Views
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Nasdaq Gains Over 50 Points; US Producer Prices Increase In March
Via Benzinga
Topics Stocks
Exposures US Equities
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
ENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023
Via InvestorPlace
Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis
Via ACCESSWIRE
Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals
Via ACCESSWIRE
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
Exposures COVID-19
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
From MediWound Ltd.
Via GlobeNewswire
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.